Positive outlook for UK biotech jobs

Article

Pharmaceutical Technology Europe

A significant increase in the recruitment of contract staff is expected during the next 12 months in the UK biotechnology sector, according to a survey conducted by SRG, which provides personnel to various science-based sectors.

A significant increase in the recruitment of contract staff is expected during the next 12 months in the UK biotechnology sector, according to a survey conducted by SRG, which provides personnel to various science-based sectors.

“The results of our latest survey clearly show that the outlook for 2010 is looking positive as, from all the sectors surveyed, biotechnology is predicting the second highest increased permanent staff recruitment during 2010,” Ena Vieira, a biotechnology industry specialist for SRG, explained in a press statement.

The largest increase in staff recruitment is expected to come from the oil/gas/petrochemicals sector. However, the survey also added that nearly three times as many companies as in 2009 have forecast an increased requirement for permanent staff in 2010. In general, SRG expects recruitment in industries across the board to be stable for the next 12 months.

This is a much brighter outlook compared with 2009 when the UK science labor market cut both permanent and contract staff.

Vieira said: “With the unstable economic situation over the last 12 months, biotech companies have become even more focused on the commercial returns of their products. This has led to a trend emerging, showing that they are now seeking to recruit more commercially focused staff whilst still requiring them to have suitable scientific skills.”

The survey was completed by more than 550 UK employers of scientists, including biotechnology, food, chemicals, pharmaceuticals, oil, petrochemical and healthcare companies, research institutes and government departments.

www.srg.co.uk

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content